A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
Public ClinicalTrials.gov record NCT05508867. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers are looking for a way to treat classical Hodgkin lymphoma (cHL) that is relapsed (the cancer has come back after treatment) or refractory (current treatment has stopped working to slow or stop cancer growth). Researchers want to learn if people who receive coformulated favezelimab/pembrolizumab (MK-4280A) live longer without the cancer getting worse compared to those who receive chemotherapy.
Study identification
- NCT ID
- NCT05508867
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 203 participants
Conditions and interventions
Conditions
Interventions
- favezelimab/pembrolizumab Biological
- bendamustine Drug
- gemcitabine Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 17, 2022
- Primary completion
- Sep 2, 2025
- Completion
- Jan 7, 2026
- Last update posted
- Aug 31, 2026
2022 – 2026
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Arizona Cancer Center - North Campus ( Site 2216) | Tucson | Arizona | 85719 | — |
| UCLA Hematology/Oncology - Santa Monica ( Site 2208) | Los Angeles | California | 90404 | — |
| Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site | Torrance | California | 90502 | — |
| Moffitt Cancer Center ( Site 2200) | Tampa | Florida | 33612 | — |
| University of Kentucky Chandler Medical Center ( Site 2201) | Lexington | Kentucky | 40536 | — |
| University of Maryland-Greenebaum Comprehensive Cancer Center ( Site 2210) | Baltimore | Maryland | 21201 | — |
| Johns Hopkins University-The Sidney Kimmel Comprehensive Cancer Center ( Site 2206) | Baltimore | Maryland | 21231 | — |
| University of Michigan ( Site 2215) | Ann Arbor | Michigan | 48109 | — |
| Cancer and Hematology Centers of Western Michigan ( Site 2222) | Grand Rapids | Michigan | 49503 | — |
| Rutgers Cancer Institute of New Jersey ( Site 2217) | New Brunswick | New Jersey | 08903 | — |
| Roswell Park Cancer Institute ( Site 2220) | Buffalo | New York | 14263 | — |
| University Hospitals Cleveland Medical Center ( Site 2214) | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic-Taussig Cancer Center ( Site 2203) | Cleveland | Ohio | 44195 | — |
| AHN West Penn Hospital ( Site 2213) | Pittsburgh | Pennsylvania | 15224 | — |
| UPMC Hillman Cancer Center ( Site 2205) | Pittsburgh | Pennsylvania | 15232 | — |
| Fred Hutchinson Cancer Center ( Site 2212) | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 89 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05508867, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 31, 2026 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05508867 live on ClinicalTrials.gov.